# Thymosin Alpha-1 Dosage in the Research: Regimens, Routes, and Pharmacokinetics

> Thymosin Alpha-1 dosage as studied — the regimens used in hepatitis, sepsis, and COVID-19 trials, reported by population and route, plus subcutaneous pharmacokinetics. No human dosing guidance.

What was given, to whom, by what route — logged as research data, never as instruction.

## Start here

This page reports Thymosin Alpha-1 dosage exactly as it appears in the published trials — and nothing more. It is not a how-to and not a recommendation; you will not find a "take this much" line anywhere on it, because that line would be medical advice, and this is a literature digest. What you will find is what researchers actually administered: which amount, to which group of patients, by which route, for how long. Almost everything was given as a subcutaneous injection (a shot under the skin). The most-studied regimen, used in long-term hepatitis, is a small twice-weekly dose. Sepsis trials gave it more often for about a week. Below those numbers sits the pharmacology — how fast the peptide peaks and clears — which explains why the dosing schedules look the way they do. Read it as a record of the science, not as a plan.

## Thymosin alpha 1 dosage

Across four decades of literature, the studied thymosin alpha 1 dosage clusters tightly. A comprehensive review reports single subcutaneous doses ranging from `0.8-6.4 mg`, with multiple-dose regimens of `1.6-16 mg` over five to seven days [4]. The most common chronic regimen — the hepatitis B and C standard — is `1.6 mg subcutaneous twice weekly` [9]. These are reported here strictly as study-attributed research data: amounts administered to defined patient populations by a defined route, not figures for anyone to act on.

## How it was dosed across the trials

The regimens track the indication. In the ETASS and TESTS sepsis trials the peptide was studied at `1.6 mg subcutaneous every 12 hours for five to seven days` in adult ICU patients [2][3]. COVID-19 cohort work used `1.6 mg subcutaneous daily` [6]. A severe-pancreatitis pilot studied `3.2 mg subcutaneous twice daily for 7 days`, and a non-small-cell lung cancer chemoradiotherapy-adjunct study used weekly subcutaneous injection for up to twelve months [4]. Each of these is an amount given to a specific studied population by the subcutaneous route — recorded, not endorsed, and not transferable to any unstudied use.

## Pharmacokinetics — why the schedule looks like this

The dosing rhythm follows the pharmacology. After subcutaneous injection in human volunteers, Thymosin Alpha-1 shows an elimination half-life of about `2 hours`, with time-to-peak around `1-2 hours`, peak concentration of `30-80 mcg/L`, and a volume of distribution (`~30-40 L`) consistent with extracellular-fluid distribution; blood levels return toward baseline within about 24 hours [8]. It is highly acidic (isoelectric point near 4.2), does not bind plasma proteins extensively, and is degraded by tissue and circulating aminopeptidases — which is exactly why the therapeutic effect outlasts the brief plasma presence and why intermittent dosing is feasible despite the short half-life [8]. It is supplied lyophilized, and the essential N-terminal acetylation must be preserved for activity.

## Routes studied

The subcutaneous injection is the primary clinical route in essentially every trial [4]. Mechanistic work has used in-vitro and ex-vivo systems, and preclinical studies have used in-vivo murine models (including the intraperitoneal route) [5][10]. There is no established oral, intranasal, or transdermal route in the human clinical record — the studied evidence is a subcutaneous-injection record, and that is how it is reported here.

---

A standing record of what the thymus's quiet peptide has been measured to do — read from the literature, not whispered from a clinic, and nothing here is dispensed, prescribed, or sold.